Cart
sales@molnova.com
MN-64
CAS No. 92831-11-3
MN-64( MN-64 | MN 64 | MN64 )
Catalog No. M17668 CAS No. 92831-11-3
MN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | In Stock |
|
| 10MG | 58 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 192 | In Stock |
|
| 100MG | 312 | In Stock |
|
| 500MG | 743 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMN-64
-
NoteResearch use only, not for human use.
-
Brief DescriptionMN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
-
DescriptionMN-64 is a potent and selective inhibitor of Tankyrase 1 and 2 (IC50 = 6 and 72 nM, respectively). MN-64 blocks Wnt signaling in HEK293 cells containing a Wnt pathway reporter system. Tankyrases are ADP-ribosyltransferases that play key roles in various cellular pathways, including the regulation of cell proliferation, and thus, they are promising drug targets for the treatment of cancer.
-
In VitroMN-64 is a potent tankyrase 1 inhibitor, with IC50s of 6 nM, 72 nM, 19.1 μM, 39.4 μM for TNKS1, TNKS2, ARTD1 and ARTD2, respectively. MN-64 effectively inhibits Wnt/β-catenin at 1 μM, and blocks STF luciferase activity at 200 nM.
-
In Vivo——
-
SynonymsMN-64 | MN 64 | MN64
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorTankyrase
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number92831-11-3
-
Formula Weight264.32
-
Molecular FormulaC18H16O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 100 mg/mL. 378.33 mM;
-
SMILESCC(C)c1ccc(cc1)c1cc(=O)c2ccccc2o1
-
Chemical Name2-[4-(1-Methylethyl)phenyl]-4H-1-benzopyran-4-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Narwal M, et al. J Med Chem. 2013 Oct 24;56(20):7880-9.
molnova catalog
related products
-
CB-103
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
-
Brontictuzumab
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.
-
YO-01027
YO-01027 (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.
